Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
1/3/2024 | Buy → Hold | Needham | |
11/8/2023 | Outperform → Mkt Perform | Raymond James | |
7/18/2023 | $205.00 → $120.00 | Buy → Hold | Stifel |
7/10/2023 | $173.00 | Equal Weight | Wells Fargo |
DEFA14A - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
Second Quarter 2024 Highlights: Consolidated revenue was $496.3 million; Healthcare revenue was $343.9 million; Non-healthcare revenue was $152.4 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.86. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Results: Consolidated revenue was $496.3 million, comprised of healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,600. Consolidated GAAP
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the cal
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Bob Chapek Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Bob Chapek has been appointed to Masimo's Board of Directors. Mr. Chapek was Chief Executive Officer of The Walt Disney Company, one of the world's largest media and entertainment companies, from February 2020 to November 2022, successfully leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and global reach of its streaming services, made transformative changes to its parks and resorts worldwide, and leveraged new and innovative technologies to bring stories to life in more immer
Rolf A. Classon Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Rolf A. Classon has been appointed to Masimo's Board of Directors. Mr. Classon is an experienced medical technology executive and board member. From October 2002 until his retirement in July 2004, he was Chairman of the Executive Committee of Bayer HealthCare AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon has served as Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since 2011,
Company to Donate $100,000 of Stork™ Smart Home Baby Monitoring Systems and Take Part in a March of Dimes Donation Matching Program Masimo (NASDAQ:MASI), a global leader in innovative monitoring technologies used in top hospitals, and March of Dimes, the leading non-profit organization fighting to improve health outcomes for all moms and babies, are launching a partnership to support new parents with babies in the Neonatal Intensive Care Unit (NICU). Between 9 to 13 percent of babies born require a stay in the NICU due to complex medical needs1, and many babies born preterm, with birth defects, or with severe health complications spend their first days in the NICU. Through this partnershi
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
Masimo SET® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 Clinical Studies Masimo (NASDAQ:MASI) Signal Extraction Technology®, or SET®, pulse oximetry – industry-leading, clinically proven, and used by top hospitals everywhere – continues to overcome the limitations of conventional pulse oximetry and offers unrivaled accuracy through ongoing innovation. As of 2024, Masimo's foundational SET® technology is now the primary pulse oximetry technology at all ten top U.S. hospitals,1 and is used to monitor more than 200 million patients a year around the w
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
Stifel upgraded Masimo from Hold to Buy and set a new price target of $170.00 from $148.00 previously
Wells Fargo upgraded Masimo from Equal Weight to Overweight and set a new price target of $160.00 from $117.00 previously
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
- Reuters Citing CNBC
Highlights Quentin Koffey's Actions That Have Flown in the Face of Good GovernanceMasimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numerous actions Politan has taken to advance its own agenda at the expense of Masimo's governance and stockholder value.